Drugs / XKDCT225
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06782425 | Jan 2025 → Jan 2028 expected | — | Shenzhen Celconta Life Science Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XKDCT225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06782425 ↗ |
| Modality | Cell therapy | “Autologous targeted claudin18.2 chimeric antigen receptor T cell injection” NCT06782425 ↗ |